is...wondering why God loves us so much?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Let the good times Roll!!!
i did already
November 19, 2010 - ex-dividend date - What's the big deal of this?
November 23, 2010 - must be a shareholder - self explanatory
December 7, 2010 - payout date - self explanatory
And will the stock automatically drop 8 bucks? if so on which day? Payout or Ex-Div?
Can we short it from now?
edit it again will ya lol
Nitwit :) :) I would be honored ! :)
YAK - I have a Dividend question - can you explain the 3 dates to me:
Wynn Resorts, Limited Declares $8 Cash Dividend
Tuesday, 2 Nov 2010 04:01pm EDT
Wynn Resorts, Limited announced that its Board of Directors declared a cash dividend of $8.00 per share on its outstanding common stock. This dividend will be payable on December 7, 2010, to stockholders of record on November 23, 2010. The stock will begin to trade ex-dividend on November 19, 2010.
Im in!!! :) FAVORITE!
HGSI APPROVED 13 TO 2
YOU WILL LOVE THIS!
Quantitative Easing Explained
kuwlness, prepare yourself to watch the video, it's going to be posted on the website. read the PR i posted all info is in there to log on. I'm in it to win it as well. Only encouraging to say the least.
Also, this is the first presentation for the CEO, highly unlikely he'll come out with bad news.
I Will, i'm waiting on a response back from IR
INOL keeps dropping - remember this one day wonder?
I'm tired. We need a bouncer.
you too - :)
Nice move Fed
It's super bad news
Saba7 el noor!
AMRN presenting @ Lazard 310pm.
MELA Down Big PM - FDA Notes released.
GM SSS
A Case against Lovaza -
Prescription fish oil capsules (Lovaza) don't help atrial fibrillation, study says
Share 0diggsdigg
By Thomas H. Maugh II, Los Angeles Times
November 15, 2010|10:02 a.m.
E-mail Print Share Text Size la-heb-fish-oil-capsules-20101115
If you have been taking fish oil supplements in an effort to smooth out erratic heart beats caused by atrial fibrillation, you can save your money, researchers said Monday. The largest study of the supplements ever conducted showed that a prescription form of omega-3 polyunsaturated fatty acids called Lovaza is worthless for treating atrial fibrillation, providing no benefit whatsoever.
"This is data that we've needed sorely," Dr. Christine Albert of Brigham and Women's Hospital in Boston, who was not involved in the study, said at a news conference. "There are a lot of patients taking these supplements."
Atrial fibrillation, which affects an estimated 2.2 million Americans, occurs when the heart beats erratically, making it difficult to pump blood throughout the body. Blood can pool in the heart, forming clots that can travel to the brain and cause strokes. An estimated 15% of strokes are caused by atrial fibrillation.
Fish oil is thought to help heart disease, and many patients take it in an effort to help atrial fibrillation as well. Several small studies have produced conflicting results about its value. Dr. Peter R. Kowey of the Jefferson Medical College in Philadelphia and his colleagues studied 663 patients with atrial fibrillation but no substantial structural heart disease. Half were given daily Lovaza and half a placebo for six months. The endpoint was when the first recurrence of fibrillation happened.
The team reported at a Chicago meeting of the American Heart Assn. and online in the Journal of the American Medical Assn. that they observed no significant differences between the two groups. The drug was "extremely well tolerated," Kowey said, but it simply provided no benefit. "We have demonstrated incontrovertibly that patients who received the drug did no better than patients who received placebo."
If the prescription-strength capsules have no effect, experts said, it is unlikely that over-the-counter supplements will provide any benefit.
Copyright © 2010, Los Angeles Times
3eed Mubarak SSS
Amarin to Present at Lazard Capital Markets Annual Healthcare Conference
DUBLIN and MYSTIC, Conn., Nov. 15, 2010 /PRNewswire via COMTEX/ -- Amarin Corporation plc /quotes/comstock/15*!amrn/quotes/nls/amrn (AMRN 3.46, +0.06, +1.76%) today announced that it is scheduled to present at the Lazard Capital Markets 7th Annual Healthcare Conference on Tuesday, November 16, 2010 at 3:10pm. Representing Amarin at this conference will be Joseph Zakrzewski, Chairman and Chief Executive Officer and John Thero, President. This conference will be held at the St. Regis in New York City.
A live audio webcast of the presentation will be available at the following URL:
http://www.wsw.com/webcast/lz8/amrn/
About Amarin
Amarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (ethyl icosapentate), which is presently being investigated in two Phase 3 clinical trials, one for the treatment of patients with very high triglyceride levels and the other for the treatment of patients with high triglycerides with mixed dyslipidemia on statin therapy. Both of these Phase 3 trials are conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. For more information please visit www.amarincorp.com.
Investor Contact Information:
John F. Thero
President
In U.S.: +1 (860) 572-4979
investor.relations@amarincorp.com
Lee M. Stern
The Trout Group
In U.S.: +1 (646) 378-2922
lstern@troutgroup.com
Media Contact Information:
David Schull or Martina Schwarzkopf, Ph.D.
Russo Partners
In U.S.: +1 (212) 845-4271 or +1 (212) 845-4292 (office)
+1 (347) 591-8785 (mobile)
david.schull@russopartnersllc.com
martina.schwarzkopf@russopartnersllc.com
Mark Swallow or David Dible
Citigate Dewe Rogerson
In U.K.: +44 (0)207 638 9571
mark.swallow@citigatedr.co.uk
Hi Matt - Is Post Stream off line?
AMRN - CANACCORD - Price Target $7
thanks - for those wondering; the question was:
"Do you think the rerouting of ssyo to ameta website was ill willed?"
So we know it was a paying ihub member...hmm...Good Job Yak! :) Wish i had an ounce of your judgement on these trades.
crazy! still down
DF? Deer? so, another day or 2
SMT a bad buy here Yak?
lol blah!
correction 55% blah!
we wait ! 50% shave sux !
HOW!? this is rediculous..you called it so right !
AMRN CC @ 11AM
They should've renamed ABKFQ - ABK-F U lol pardon my french
AHAHAHAHAHAH!
ZAGG pop
lol oops.